Enfusion, Inc. (NYSE:ENFN) General Counsel Sells $13,488.67 in Stock

Enfusion, Inc. (NYSE:ENFN) General Counsel Matthew Campobasso sold 1,651 shares of the company’s stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $8.17, for a total value of $13,488.67. Following the completion of the sale, the general counsel now owns 54,301 shares in the company, valued at approximately $443,639.17. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Enfusion Stock Performance

ENFN stock opened at $8.40 on Monday. Enfusion, Inc. has a 1 year low of $7.52 and a 1 year high of $11.56. The firm has a market cap of $1.08 billion, a P/E ratio of 277.43, a PEG ratio of 1.90 and a beta of 0.96. The stock’s 50 day moving average price is $9.15 and its 200 day moving average price is $9.10.

Enfusion (NYSE:ENFN) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.05). Enfusion had a return on equity of 6.60% and a net margin of 1.40%. The business had revenue of $48.05 million for the quarter, compared to analysts’ expectations of $47.67 million. During the same period in the prior year, the company earned $0.04 EPS. On average, research analysts predict that Enfusion, Inc. will post 0.09 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on ENFN. Bank of America upped their price target on Enfusion from $8.00 to $9.00 and gave the stock an “underperform” rating in a report on Wednesday, March 13th. The Goldman Sachs Group lowered Enfusion from a “neutral” rating to a “sell” rating and reduced their target price for the company from $9.00 to $8.00 in a research note on Wednesday, February 28th. Finally, Morgan Stanley started coverage on Enfusion in a research note on Friday, May 10th. They issued an “overweight” rating and a $11.00 target price on the stock. Three analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $9.33.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ENFN. Barclays PLC lifted its stake in shares of Enfusion by 29.0% during the 3rd quarter. Barclays PLC now owns 10,809 shares of the company’s stock worth $96,000 after purchasing an additional 2,430 shares during the period. Swiss National Bank increased its holdings in shares of Enfusion by 55.7% during the 3rd quarter. Swiss National Bank now owns 49,500 shares of the company’s stock worth $444,000 after buying an additional 17,700 shares during the last quarter. Algert Global LLC acquired a new stake in shares of Enfusion during the 3rd quarter worth $139,000. Hudson Bay Capital Management LP increased its holdings in shares of Enfusion by 29.7% during the 3rd quarter. Hudson Bay Capital Management LP now owns 460,084 shares of the company’s stock worth $4,127,000 after buying an additional 105,236 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Enfusion by 17.2% during the 3rd quarter. Vanguard Group Inc. now owns 3,487,815 shares of the company’s stock worth $31,286,000 after buying an additional 512,479 shares during the last quarter. Hedge funds and other institutional investors own 81.05% of the company’s stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.